^
Association details:
| Biomarker: | CDYL2 overexpression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer
Published date:
01/03/2022
Excerpt:
More importantly, HER2+ patients with high circCDYL2 had higher recurrence rate after trastuzumab treatment....Trastuzumab-resistance of HER2+ BC cells with high circCDYL2 could be reversed by FAK or GRB7 inhibitor....circCDYL2-GRB7-FAK complex plays a critical role in maintaining HER2 signaling, which contributes to trastuzumab resistance and circCDYL2 is a potential biomarker for trastuzumab-resistance in HER2+ BC patients.
DOI:
10.1186/s12943-021-01476-7
